EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors

Kavitha Däster, Jürgen Hench, Maren Diepenbruck, Katrin Volkmann, Adelin Rouchon, Marta Palafox, Jorge Gomez Miragaya, Bogdan Tiberius Preca, Christian Kurzeder, Walter Paul Weber, Mohamed Bentires-Alj, Savas Deniz Soysal und 1 weitere

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-024-07502-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Kavitha Däster und 12 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center Zurich, Zurich, Switzerland. Kavitha.daester@brust-zentrum.ch. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, DNA Methylation, Poly(ADP-ribose) Polymerase Inhibitors, Promoter Regions, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Dr Hans Altschüler Stiftung, Illumina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Most triple-negative breast cancers (TNBC) are sporadic in nature and often associated with dysfunction of the BRCA1 or BRCA2 genes. Since somatic BRCA mutations are rare in breast cancer (BC), this dysfunction frequently is the result of BRCA promoter methylation. Despite the phenotypic similarities of these tumors to those with germline or somatic BRCA mutation, the evidence of response to PARP inhibitors is unclear.

Methods

We analyzed the prevalence of BRCA promoter methylation in 29 BC metastases through the well-established Illumina Infinium EPIC Human Methylation Bead Chip. In cases with BRCA methylation, the xenograft of the same tumor was tested. Additionally, we compared BC xenografts with an identified BRCA methylation to their matched primary tumors and subsequently investigated the efficacy of PARP inhibitors on tumor organoids from a BRCA2 promoter-methylated BC.

Results

BRCA2 promotor hypermethylation was identified in one pleural metastasis of a young patient as well as in the xenograft tissue. We also identified five more xenograft models with BRCA2 promotor hypermethylation. Analysis of one matched primary tumor confirmed the same BRCA2 methylation. PARP inhibitor treatment of tumor organoids derived from the BRCA2 methylated xenograft tumor tissue of the young patient showed a significant decline in cell viability, similar to organoids with somatic BRCA1 mutation, while having no effect on organoids with BRCA1 wildtype.

Conclusion

BRCA promotor hypermethylation seems to be a rare event in metastatic BC but is preserved in subsequent xenograft models and might represent an attractive therapeutic marker for PARP inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDNA MethylationPoly(ADP-ribose) Polymerase InhibitorsPromoter Regions, GeneticBRCA2 ProteinBRCA1 ProteinBiomarkers, TumorHumansFemaleAnimalsXenograft Model Antitumor AssaysMiceCell Line, TumorMiddle AgedAdultGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

BRCA promoter methylationMetastatic breast cancerPARP inhibitorsTriple-negative breast cancer

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinBRCA1 ProteinBiomarkers, TumorBRCA2 protein, humanBRCA1 protein, human

Autor:innen und Institutionen

  • Breast Center Zurich, Zurich, Switzerland. Kavitha.daester@brust-zentrum.ch.
  • University of Basel, Basel, Switzerland. Kavitha.daester@brust-zentrum.ch.
  • Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Tumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
  • University of Basel, Basel, Switzerland.
  • Breast Center, University Hospital Basel, Basel, Switzerland.

Förderung

  • European Research Council
  • Dr Hans Altschüler Stiftung
  • Illumina
  • the Swiss National Science Foundation
  • the Krebsliga Beider Basel
  • the Swiss Cancer League
  • the Swiss Personalized Health Network
  • Department of Surgery, University Hospital Basel

Zitieren

APA

Däster, K., Hench, J., Diepenbruck, M., Volkmann, K., Rouchon, A., Palafox, M., Miragaya, J. G., Preca, B. T., Kurzeder, C., Weber, W. P., Bentires-Alj, M., Soysal, S. D., & Muenst, S. (2025). BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07502-8

Vancouver

Däster K, Hench J, Diepenbruck M, Volkmann K, Rouchon A, Palafox M, et al. BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07502-8

BibTeX
@article{Dster2025,
  author = {Däster, Kavitha and Hench, Jürgen and Diepenbruck, Maren and Volkmann, Katrin and Rouchon, Adelin and Palafox, Marta and Miragaya, Jorge Gomez and Preca, Bogdan Tiberius and Kurzeder, Christian and Weber, Walter Paul and Bentires-Alj, Mohamed and Soysal, Savas Deniz and Muenst, Simone},
  title = {BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-024-07502-8}
}
Kostenlos starten →